In­tra-Cel­lu­lar on track for an­oth­er Caply­ta la­bel ex­pan­sion af­ter pos­i­tive Ph3 de­pres­sion da­ta

In­tra-Cel­lu­lar Ther­a­pies’ Caply­ta sig­nif­i­cant­ly im­proved symp­toms in a late-stage ma­jor de­pres­sive dis­or­der tri­al, mark­ing a step in the drug’s jour­ney to be­com­ing a pipeline-in-a-pill.

Atyp­i­cal an­tipsy­chot­ic Caply­ta is al­ready ap­proved for schiz­o­phre­nia and bipo­lar de­pres­sion. Ac­cord­ing to Jef­feries an­a­lysts, the drug is “be­com­ing a pipeline-in-a-pill” and could reach $2 bil­lion in peak sales in these two in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER